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Intrathecal immunoglobulin A and G
antibodies to synapsin in a patient with
limbic encephalitis
ABSTRACT
Objective: To report on the identification of intrathecally synthesized immunoglobulin A (IgA) and
immunoglobulin G (IgG) antibodies to synapsin, a synaptic vesicle-associated protein, in a patient
with limbic encephalitis.
Methods: Methods included clinical characterization, indirect immunofluorescence, immunopre-
cipitation, mass spectrometry, immunoblots of wild-type and synapsin I/II/III knockout mice, and
cell-based assays with synapsin Ia, Ib, IIa, and IIb plasmids.
Results: A 69-year-old man presented with confusion, disorientation, seizures, and left hippocampal
hyperintensities on MRI. CSF examinations revealed an intrathecal IgA and IgG synthesis. Except
for IgG antibodies to voltage-gated potassium channels in CSF, screening for known neuronal autoan-
tibodies in serum and CSF was negative. However, indirect immunofluorescence using the patient’s
CSF showed binding of IgA to mouse hippocampus, amygdala, and cerebellum. Immunoprecipitation
with CSF IgA followed by mass spectrometry identified synapsin as autoantigenic target. Knockout
tissues and cell-based assays confirmed that IgA and IgG in the patient’s CSF and serum reacted with
synapsin Ia, Ib, and IIa. Calculation of antibody indices proved intrathecal synthesis of anti-synapsin IgA
and IgG. The patient responded clinically to immunotherapy but developed left hippocampal atrophy.
CSF IgA or IgG of the patient did not bind to live, unfixed, and nonpermeabilized mouse hippocampal
neurons, compatible with synapsin being an intracellular antigen.
Conclusions: This report identifies isoforms of the synaptic vesicle-associated protein synapsin as tar-
gets of intrathecally produced IgA and IgG antibodies in a patient with limbic encephalitis. Future stud-
ies should clarify the prevalence and pathogenic relevance of anti-synapsin antibodies in limbic
encephalitis. Neurol Neuroimmunol Neuroinflamm 2015;2:e169; doi: 10.1212/NXI.0000000000000169
GLOSSARY
AI 5 antibody index; CBA 5 cell-based assay; IgA 5 immunoglobulin A; IgG 5 immunoglobulin G; VGKC 5 voltage-gated
potassium channels.
Limbic encephalitis is characterized by memory dysfunction, seizures, behavioral changes, and
mesiotemporal involvement on imaging or neuropathologic studies, and is frequently associated
with antibodies to neuronal autoantigens.1 We report on the identification of synapsin, a syn-
aptic vesicle-associated protein, as an antigenic target of intrathecally synthesized immunoglob-
ulin A (IgA) and immunoglobulin G (IgG) in a patient with limbic encephalitis.
METHODS Standard protocol approvals, registrations, and patient consents. The study was approved by the institutional
review board of Charité–Universitätsmedizin Berlin (EA1/083/15) and written informed consent was obtained from the patient
reported in this study.
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Laboratory methods. Details of the laboratory
methods used in this work, including indirect immunofluo-
rescence, immunoprecipitation, mass spectrometry, synap-
sin knockout mice, cell-based assays, and calculation of
antibody indices (AIs) are provided in appendix e-1 at
Neurology.org/nn.
RESULTS Case report. In August 2013, a 69-year-old
man with a history of a previous seizure in March
2012 presented with confusion, disorientation, and
a generalized epileptic seizure. Cerebral MRI revealed
signal hyperintensities in the left mesial temporal lobe
Figure 1 Clinical findings and CNS immunoreactivity of CSF IgA of a patient with limbic encephalitis
(A) Cranial MRI of a 69-year-old man with limbic encephalitis demonstrates left mesiotemporal signal hyperintensities on coronal fluid-attenuated inver-
sion recovery sequences (arrow, see also enlarged region) at first presentation in August 2013, which progressed into hippocampal atrophy (arrow, see
also enlarged region) until September 2014. (B) Repeated cognitive screening by DemTect and Mini-Mental State Examination (MMSE) show mild cog-
nitive impairment. (C) Time course of clinical symptoms, immunotherapies, and calculated percentage of intrathecally synthesized immunoglobulin A
(IgA) or immunoglobulin G (IgG) of the total IgA or IgG in CSF. (D) Fixed and permeabilized mouse hippocampus sections were stained with patient
CSF at a dilution of 1:100 (left panels) and a FITC-coupled antihuman IgA secondary antibody, demonstrating strong immunoreactivity within the neuro-
pilar regions of the cornu ammonis and dentate gyrus including a prominent signal mapping to the mossy fiber tract. Immunoreactivity of the patient’s
CSF IgA colocalized with that of ZnT3, a marker of glutamatergic mossy fiber terminals expressed in synaptic vesicles. Control CSF adjusted to the
same IgA concentration as the patient’s CSF revealed no signal (right panels). Dapi staining was used to visualize nuclei. (E) Mouse cerebellum sections
were stained with patient and control CSF as described above, demonstrating binding of patient CSF IgA to the molecular layer and the granule cell
layer glomeruli, but not to Purkinje cells. AZT 5 azathioprine; CA 5 cornu ammonis; Dapi 5 49,6-Diamidin-2-phenylindol; DG 5 dentate gyrus; gcl 5
granule cell layer; IVIg5 IV immunoglobulin; Mf5mossy fiber tract; ml5molecular layer; pcl5 Purkinje cell layer; Slm5 stratum lacunosummoleculare;
So 5 stratum oriens; Sp 5 stratum pyramidale; Sr 5 stratum radiatum.
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(figure 1A). EEG showed left frontocentral slowing and
few epileptiform discharges. Neuropsychological testing
revealed mild cognitive impairment (figure 1B). CSF
analyses demonstrated a lymphocytic pleocytosis (22
cells/mL), elevated protein (1.43 g/L, reference ,0.5
g/L), and CSF-specific oligoclonal IgG bands with
47% of the total IgG in CSF being synthesized
intrathecally (figure 1C). Further CSF examinations
additionally revealed a strong intrathecal IgA synthesis,
persisting until the last follow-up CSF examination in
June 2014.
Virologic and bacteriologic studies were normal.
Screening of serum and CSF for known antineuronal
antibodies (NMDA receptor, AMPA receptor, GABAB
receptor, LGI1, CASPR2, glycine receptor, Hu, Ri, Yo,
Tr, Ma/Ta, GAD, amphiphysin, aquaporin-4) using
cell-based assays (EUROIMMUN, Lübeck, Germany)
as well as testing of serum for antinuclear antibodies and
antibodies to gliadin was negative. However, IgG anti-
bodies to voltage-gated potassium channels (VGKC)
were detected by radioimmunoprecipitation assay in
CSF (17 pmol/L, reference ,2 pmol/L, see appendix
e-2), but not in serum. Intrigued by the patient’s strong
intrathecal IgA synthesis, we investigated a possible reac-
tivity of IgA in the patient’s CSF with fixed and permea-
bilized mouse hippocampus sections by indirect
immunofluorescence. This demonstrated strong binding
of IgA in the patient’s CSF to the neuropilar regions of
theCornu ammonis and dentate gyrus, including a prom-
inent signal in the mossy fiber tract (figure 1D). Immu-
noreactivity of the patient’s CSF IgA colocalized with
that of the zinc transporter ZnT3, a marker of glutama-
tergic mossy fiber terminals expressed in synaptic vesicles.
CSF IgA also stained the amygdala (figure e-1) and the
molecular and granular layers, but not Purkinje cells, in
mouse cerebellum (figure 1E). No immunoreactivity was
observed in mouse brain sections stained with control
CSF applied at the same IgA concentration as the pa-
tient’s CSF (figure 1, D and E).
The patient was diagnosed with limbic encephalitis
associated with antineuronal antibodies. Whole-body
CT, urologic examination, esophagogastroduodenos-
copy, and colonoscopy did not reveal an underlying
tumor. Immunotherapies (summarized in figure 1C)
were associated with clinical improvement, but MRI
revealed progressive left hippocampal atrophy (figure
1A). After a relapse in November 2014, the patient was
switched to rituximab. Under this therapy, he is cur-
rently asymptomatic except for mild cognitive impair-
ment and has had no further relapses.
Synapsin Ia, Ib, and IIa as target antigens. CSF IgA of the
patient, but not of a control, detected proteins between
70 and 100 kDa in immunoblots frommouse brain ho-
mogenates. Subcellular fractionation showed enrich-
ment of these proteins in synaptic vesicles (figure 2A).
CSF IgA of the patient, but not of a control, immuno-
precipitated the 70–100 kDa proteins (figure 2B),
which were subsequently excised from a Coomassie
gel (figure 2C) and analyzed by mass spectrometry,
demonstrating sequences from both synapsin I and syn-
apsin II (figure 2D).
To confirm the specificity of the patient’s anti-
bodies for synapsin and to identify the targeted syn-
apsin isoforms, we carried out immunoblots with
brain homogenates from wild-type, synapsin I, syn-
apsin II, or synapsin I/II/III knockout mice (figure
2E). Reactivity of the patient’s CSF IgA with synapsin
Ia, Ib, and IIa was abolished in the respective knock-
out mice, indicating that the patient’s antibodies rec-
ognize synapsin Ia, Ib, and IIa. While the patient’s
CSF IgA did not detect synapsin IIb, it reacted with
an approximately 80 kDa band in synapsin I/II/III
knockout mice, possibly representing an additional
autoantigen of unknown identity. Immunohisto-
chemical staining of wild-type mouse brain sections
by the patient’s CSF IgA was abrogated in synapsin
I/II/III knockout tissue (figure 2F).
Cell-based assays (CBAs) with fixed and permeabi-
lized HEK293 cells transfected with synapsin Ia, Ib,
IIa, or IIb plasmids further confirmed binding of the pa-
tient’s CSF IgA to synapsin Ia, Ib, and IIa, but not IIb
(figure 3A). Staining of fixed and permeabilized mouse
hippocampus sections and fixed and permeabilized pri-
mary mouse hippocampal neurons with CSF IgA and
commercial anti-synapsin I/II antibodies demonstrated
colocalization of both signals (figure 3B).
CSF IgG of the patient likewise reacted with synap-
sin Ia and Ib, and weakly with synapsin IIa, and colo-
calized with commercial anti-synapsin I/II antibodies
and patient CSF IgA in mouse hippocampus sections
(figure e-2). Furthermore, IgA and IgG in the patient’s
serum reacted with synapsin Ia, Ib, and IIa (figure e-3).
Screening of sera of 17 healthy controls demonstrated
no IgG antibodies to synapsin Ia (figure e-4). IgA anti-
bodies to synapsin were not determined in the healthy
controls.
In contrast to the binding of fixed and permeabilized
synapsin-transfected HEK293 cells as well as of fixed
and permeabilized primary hippocampal neurons by
the patient’s CSF, staining of live, unfixed, and non-
permeabilized HEK293 cells transfected with synapsin
Ia as well as of live, unfixed, and nonpermeabilized pri-
mary mouse hippocampal neurons with CSF IgA and
IgG and with commercial anti-synapsin I/II antibodies
revealed no immunoreactivity (figure e-5).
Finally, we determined titers of IgA and IgG to
synapsin Ia and Ib in all available CSF/serum pairs
of our patient using CBAs (appendix e-2). Subse-
quent calculation of AIs demonstrated strongly ele-
vated AI values, indicating intrathecal synthesis of
IgA and IgG to synapsin Ia and Ib (figure 3C).
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Figure 2 Identification of synapsin Ia, Ib, and IIa as antigenic targets of IgA antibodies in CSF
(A) Homogenates of mouse cerebellum and hippocampus as well as subcellular fractions from whole brain progressively enriched for
synaptic vesicles (homogenate, synaptosomes, synaptic membranes, synaptic vesicles) were blotted and incubated with patient CSF.
Bound immunoglobulin A (IgA) was detected using a peroxidase-labeled antihuman IgA secondary antibody and enhanced chemolumi-
nescence (ECL), demonstrating proteins between 70 and 100 kDa with enrichment in synaptic vesicles. Incubation with control CSF
yielded no signals. glyceraldehyde3-phosphate dehydrogenase (GAPDH) and actin served as loading controls. (B)Mouse hippocampus
homogenatewas immunoprecipitatedwith antihuman IgA (heavy chain) agarose beads preincubatedwith patient CSF. Pelleted beads
were blotted and membranes incubated with patient CSF and antihuman IgA to detect the precipitated antigens. ECL detection re-
vealed proteins of 70–100 kDa. Beads preincubated with control CSF or buffer did not precipitate proteins. (C) Coomassie-stained
gel of the immunoprecipitated proteins. The boxed area, corresponding to the upper 3 bands seen in lane 2 in (B), was excised from
the gel and subjected tomass spectrometry. (D) Mass spectrometry (MS) identified synapsin (Syn) I and Syn II as the 2 proteins with
the highest Mascot scores. Amino acid sequences of Syn I and Syn II are shown with the identified peptides highlighted in green.
(E) Brain extracts fromwild-type, Syn I, Syn II, or Syn I/II/III knockout (KO) mice were blotted and incubated with patient CSF. Bound
IgA was detected using a FITC-labeled antihuman IgA secondary antibody. Corresponding membranes were developed with com-
mercial Syn I andSyn II antibodies. Syn Ia, Ib, and IIa bandswere abolished in the respective KOmice. Syn IIbwas not detected by the
patient’s antibodies. An approximately 80 kDa band visible in Syn I/II/III KO mice could represent an additional autoantigen of
unknown identity. (F) Brain sections ofwild-type andSyn I/II/III KOmicewere incubatedwith a pan-Syn antibody, patient CSF, control
CSF, or no primary antibody (negative control) and developed with a FITC-labeled antihuman IgA secondary antibody. Immunoreac-
tivity of patient CSF in wild-type was abrogated in Syn I/II/III KO mice. IP 5 immunoprecipitation; pI 5 isoelectric point.
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Figure 3 Detection of synapsin Ia, Ib, and IIa in cell-based assays, colocalization of patient IgA and commercial
synapsin antibodies in hippocampus sections and primary hippocampal neurons, and calculation of
antibody indices
(A) Human embryonal kidney (HEK293) cells transfected with synapsin (Syn) Ia, Ib, IIa, or IIb were fixed, permeabilized, and
incubated with patient or control (CTL) CSF. Bound immunoglobulin A (IgA) was detected using an Alexa 594-coupled anti-
human IgA secondary antibody. An anti–green fluorescent protein (green fluorescent protein) antibody was used to enhance
endogenous fluorescence of transfected cells. CSF IgA-stained cells expressing Syn Ia, Ib, and IIa, but not IIb. Cells incu-
bated with control CSF showed no staining. (B) Left: Murine hippocampus sections were fixed, permeabilized, and incubated
with patient CSF (dilution 1:100) and double-stained with a commercial antibody to both Syn I and Syn II, demonstrating
colocalization of patient IgA and Syn I/II antibodies at the mossy fiber terminals in the stratum lucidum (Slu) of the CA3
region (boxed regions are depicted at higher magnification). Right: Staining of primary fixed and permeabilized murine
hippocampal neurons with patient CSF and antibodies to microtubule-associated protein 2, a somatodendritic marker,
showed a punctuate staining of CSF IgA along dendrites, indicative of a synaptic distribution. Double-staining of hippo-
campal neurons with patient CSF IgA and antibodies to Syn I/II revealed a complete overlap of signals. (C) IgA and immu-
noglobulin G (IgG) antibodies to Syn Ia/Ib in CSF and serum were titrated using cell-based assays and antibody indices were
calculated as described in the Methods. The red line indicates the cutoff of 4, AI values above which indicate an intrathecal
antibody synthesis. There was a strong intrathecal synthesis of IgA and IgG to Syn Ia/Ib throughout the course of the
disease. CA 5 cornu ammonis; Map2 5 microtubule-associated protein 2.
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DISCUSSION We report the identification of synap-
sin Ia, Ib, and IIa as autoantigenic targets of intrathe-
cally synthesized IgA and IgG in a patient with
clinically and radiologically typical limbic encephali-
tis. This is based on (1) immunoprecipitation of syn-
apsin from mouse brain homogenates by CSF IgA,
(2) abrogation of immunoreactivity to synapsin Ia,
Ib, and IIa in synapsin knockout mice, (3) detection
of synapsin Ia, Ib, and IIa by the patient’s antibodies
in CBAs, and (4) colocalization of the patient’s anti-
bodies with commercial synapsin I/II antibodies in
mouse hippocampus sections and primary neurons.
The intrathecal synthesis of synapsin IgA is a
remarkable feature of our patient. The majority of
known antineuronal antibodies are IgG isotypes and
a possible role for antineuronal IgA has only rarely been
proposed.2 We herein identify a neuronal autoantigen
using immunoprecipitation with CSF IgA. However,
although our results suggest that, besides IgG, also IgA
could be relevant in some cases of antineuronal auto-
immunity, the significance of synapsin IgA (and IgG)
currently remains elusive.
Synapsin isoforms are synaptic vesicle-associated
phosphoproteins implicated in neural development
and synaptic plasticity.3 Antibodies to synapsin I were
previously identified in serum of a patient with discoid
lupus erythematosus, but these antibodies only reacted
with denatured synapsin in immunoblots and did not
bind to frozen rat brain section or synapsin-transfected
cells.4 In contrast, in addition to the detection of dena-
tured synapsin in immunoblots, our patient’s antibodies
also recognized conformational synapsin in tissue sec-
tion and CBAs, strongly suggesting that the previously
identified antibodies to synapsin and the anti-synapsin
antibodies of our patient target different epitopes. Like-
wise, the fact that our patient’s antibodies detect con-
formational synapsin indicates a higher likelihood of
binding to the target in vivo. Anti-gliadin antibodies,
previously shown to cross-react with synapsin I and
potentially explaining neurologic deficits associated with
celiac disease,5 were not detected in our patient, exclud-
ing such cross-reactivity.
We identified antibodies to synapsin in only a single
patient so far and did not detect antibodies to synapsin in
sera of 17 healthy controls. Therefore, it is currently
impossible to draw any definite conclusions on the syn-
drome or disease specificity and the prevalence of anti-
bodies to synapsin. We also cannot rule out the
possibility that antibodies to synapsin may be an epiphe-
nomenon, e.g., secondary to cell damage. Furthermore,
the concomitant presence of antibodies to VGKC and
synapsin in the patient’s CSF raises the question which
autoimmunity may be relevant for the clinical pheno-
type. However, while VGKC antibodies became unde-
tectable in CSF (appendix e-2), intrathecal synapsin
antibody synthesis persisted throughout the course of
disease. Lack of synapsin I or synapsin II in mice triggers
epileptic seizures6 and mild cognitive impairment7 and
mutations in the gene encoding synapsin I are associated
with epilepsy,8,9 compatible with the idea that genetic as
well as autoimmune ablations of synapsins could result in
a similar clinical phenotype.
The absence of staining of live, unfixed, and nonper-
meabilized HEK293 cells transfected with synapsin Ia as
well as of live, unfixed, and nonpermeabilized primary
mouse hippocampal neurons with our patient’s CSF
IgA and IgG as well as commercial anti-synapsin I/II
antibodies was an expected result consistent with the
known intracellular expression of synapsin on the cyto-
plasmic surface of synaptic vesicles.3 This intracellular
expression of synapsin questions the accessibility for
autoantibodies and thus their potential pathogenic rele-
vance. Nevertheless, under conditions of high neuronal
activity or oxidative stress, synapsin can be extracellularly
released from glial-derived exosomes, thereby promoting
neurite outgrowth and neuronal survival through mod-
ulation of interactions between glia and neurons.10
Hypothetically, such released synapsin could be accessi-
ble for anti-synapsin IgA and IgG.
Altogether, though formal proof is lacking, a
potential pathogenic role of synapsin antibodies ap-
pears conceivable and possible pathogenic mecha-
nisms of anti-synapsin antibodies should be further
investigated. Future studies should also clarify the
prevalence of antibodies to synapsin in patients with
limbic encephalitis, other neurologic diseases, and
the general population.
AUTHOR CONTRIBUTIONS
J.P., M.H., F.B., D.G., A.P., G.A.-H., and K.R. designed the study and
analyzed data. C.O., H.H., J.P., and K.R. collected and interpreted clin-
ical data. J.P., M.H., F.B., D.G., A.P., A.M., F.C., and J.-F.Z. carried
out experiments. K.R., G.A.-H., J.P., and M.H. drafted the manuscript,
which was revised, edited, and finally approved by all authors.
ACKNOWLEDGMENT
The authors thank Antje Dräger for technical assistance.
STUDY FUNDING
No targeted funding.
DISCLOSURE
J. Piepgras, M. Höltje, C. Otto, H. Harms, and A. Satapathy report no
disclosures. F. Cesca received research support from Ministry of Education,
University and Research, Ministry of Health, Compagnia di San Paolo. F.
Befenati reports no disclosures. D. Gitler received research support from
Israel Science Foundation. A. Pich, J.-F. Zander, and G. Ahnert-Hilger
report no disclosures. K. Ruprecht is on scientific advisory boards for
Sanofi-Aventis/Genzyme, Novartis, and Roche, received travel funding
and/or speaker honoraria from Bayer Healthcare, Biogen Idec, Merck
Serono, Sanofi-Aventis/Genzyme, Teva Pharmaceuticals, Novartis, and Gu-
thy Jackson Charitable Foundation, is an academic editor for PLOS One,
receives publishing royalties from Elsevier, and received research support
from Novartis and the German Ministry of Education and Research. Go to
Neurology.org/nn for full disclosure forms.
Received May 25, 2015. Accepted in final form August 25, 2015.
6 Neurology: Neuroimmunology & Neuroinflammation
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
REFERENCES
1. Leypoldt F, Armangue T, Dalmau J. Autoimmune ence-
phalopathies. Ann NY Acad Sci 2015;1338:94–114.
2. Prüss H, Höltje M, Maier N, et al. IgA NMDA receptor
antibodies are markers of synaptic immunity in slow cog-
nitive impairment. Neurology 2012;78:1743–1753.
3. Cesca F, Baldelli P, Valtorta F, Benfenati F. The synap-
sins: key actors of synapse function and plasticity. Prog
Neurobiol 2010;91:313–348.
4. Gitlits VM, Sentry JW, Matthew LS, Smith AI, Toh BH.
Synapsin I identified as a novel brain-specific autoantigen.
J Investig Med 2001;49:276–283.
5. Alaedini A, Okamoto H, Briani C, et al. Immune cross-
reactivity in celiac disease: anti-gliadin antibodies bind to
neuronal synapsin I. J Immunol 2007;178:6590–6595.
6. Rosahl TW, Spillane D, Missler M, et al. Essential func-
tions of synapsins I and II in synaptic vesicle regulation.
Nature 1995;375:488–493.
7. Corradi A, Zanardi A, Giacomini C, et al. Synapsin-I-
and synapsin-II-null mice display an increased age-
dependent cognitive impairment. J Cell Sci 2008;121:
3042–3051.
8. Garcia CC, Blair HJ, Seager M, et al. Identification
of a mutation in synapsin I, a synaptic vesicle protein,
in a family with epilepsy. J Med Genet 2004;41:
183–186.
9. Fassio A, Patry L, Congia S, et al. SYN1 loss-of-
function mutations in autism and partial epilepsy cause
impaired synaptic function. Hum Mol Genet 2011;20:
2297–2307.
10. Wang S, Cesca F, Loers G, et al. Synapsin I is
an oligomannose-carrying glycoprotein, acts as an
oligomannose-binding lectin, and promotes neurite
outgrowth and neuronal survival when released via
glia-derived exosomes. J Neurosci 2011;31:7275–
7290.
Neurology: Neuroimmunology & Neuroinflammation 7
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/NXI.0000000000000169
2015;2; Neurol Neuroimmunol Neuroinflamm 
Johannes Piepgras, Markus Höltje, Carolin Otto, et al. 
encephalitis
Intrathecal immunoglobulin A and G antibodies to synapsin in a patient with limbic
This information is current as of November 4, 2015
Services
Updated Information &
 http://nn.neurology.org/content/2/6/e169.full.html
including high resolution figures, can be found at:
Supplementary Material
 http://nn.neurology.org/content/suppl/2015/11/04/2.6.e169.DC1
Supplementary material can be found at: 
References
 http://nn.neurology.org/content/2/6/e169.full.html##ref-list-1
This article cites 10 articles, 4 of which you can access for free at: 
Subspecialty Collections
 http://nn.neurology.org//cgi/collection/encephalitis
Encephalitis
 http://nn.neurology.org//cgi/collection/autoimmune_diseases
Autoimmune diseases
 a
http://nn.neurology.org//cgi/collection/all_cognitive_disorders_dementi
All Cognitive Disorders/Dementia
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://nn.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://nn.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
2015 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 
is an official journal of the American Academy of Neurology.Neurol Neuroimmunol Neuroinflamm 
